Trial Profile

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Oct 2023 Results (n=786) assessing develop a machine learning model to predict the effect of a change in basal insulin dose on FBG in people with T2D presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
22 Nov 2018 Results of post hoc analysis exploring whether mealtime fast-acting insulin aspart treatment provided an advantage in postprandial plasma glucose (PPG) control vs. insulin aspart in people with Type 2 diabetes receiving high doses of bolus insulin published in the Diabetic Medicine
08 Dec 2017 Results of a post-hoc analysis from Onset-2 and Onset-3 studies, presented at the 2017 Congress of the International Diabetes Federation

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com